Ketamine Therapy Proves Powerful For Treatment-Resistant Depression
A powerful FDA-approved anesthetic drug once used mainly in operating rooms and on the battlefield is quickly gaining ground as one of the most promising therapies for treatment-resistant mental health conditions.
First discovered as an anesthetic in the 1950s, ketamine has been used in the treatment of a wide range of physical conditions, especially pain management. Starting in the early 1970s, doctors began to find that it can also be very effective in alleviating mental health issues such as depression, anxiety, PTSD, and addiction. Today it is ever more frequently being studied and legally used as an off-label medication to manage conditions that are particularly resistant to treatment with conventional pharmaceuticals.
The latest in a series of recent studies has found that ketamine can quickly and dramatically decrease chronic and suicidal thoughts. Dr. Naveen Thomas is a psychiatrist who has been using ketamine in his practice for years.
“I and many of my colleagues have of course had tremendous success in using ketamine in people who are really suffering from depression. I’ve had a lot of success in treating people with Post-traumatic Stress Disorder,” Dr. Naveen said.
“And some of these folks have spent years and years doing absolutely the best they could using such a wide variety of the conventional treatments, be they various medication treatments, be they various forms of psychotherapy. We’ve seen really wonderful effects.”
Watch more:
About the Author
Psychedelic-Assissted Therapy for Veterans and Personality Improvement
Psychedelic-assisted therapy at the VA
Psychedelic-assisted therapy has recently gained mainstream acceptance among civilians, but what about for members of the military and veterans?
This therapy may soon be an option for some veterans. As “Lucid” reports, “psychedelic-assisted therapy is on the rise at some veterans administration hospitals.”
Phase 3 clinical trials of MDMA therapy to treat post-traumatic stress disorder have been so successful, with 68 percent of participants in remission, the FDA granted MDMA a special ‘Breakthrough Therapy’ designation. But this therapy is not yet available all over the country, prompting more researchers to call on the VA to create protocols for MDMA, psilocybin, and ketamine therapies. These psychedelics are still classified as Schedule 1 narcotics, and it will take political will and bipartisan support to win FDA approval.
If that happens, researchers at the forefront of these therapies hope to see VA hospitals nationwide using psychedelics to help veterans by the year 2024.
